The first R&D and innovation center in China to pass the GMP inspection by USFDA
Passed USFDA site inspection with zero deficienty in Aug 2018
Welcome to SoliPharma
SoliPharma is headquartered in Hangzhou, China and has branch office in the Greater Boston area in the United States.
SoliPharma is recognized as National High-tech Enterprise by Ministry of Science and Technology of China, as Province-level R&D Center for Highly Variable Drugs by Department of Science and Technology of Zhejiang Province.
SoliPharma has been accredited ISO 17025 by China National Accreditation Service for Conformity Assessment since 2013. We also passed GMP site inspection by USFDA with zero deficiency in 2018.
With our track record in China/U.S./Canada/European product innovation and business relationship, SoliPharma strives for delivering both innovative products (505(b)2 with modified release/new combinations) and difficult generic products (NTI, highly variable, IP hurdles etc). Leveraging global partnership with API suppliers, contract manufacturing and product distribution, SoliPharma is devoted to bringing medical products faster to meet patients’ urgent and unmet medical needs.
SoliPharma’s Focus of Therapeutic Areas
Leader in solid-state pharmaceuticals
Bring Challenging Molecules to the Global Markets
SoliPharma is a specialty pharmaceutical company. We provide technical solutions to both innovative and difficult generic products for global markets.